tbuckley/cabot-search huggingface dataset:
Global gene expression profiling of dimethylnitrosamine induced liver fibrosis in rat model, from pathological and biochemical data to microarray analysis.
Authors: Li-Jen Su, Shih-Lan Hsu, Jyh-Shyue Yang, Shiu-Feng Huang, Ann-Ping Tsou, Huei-Hun Tseng, Chi-Ying F. Huang
Journal: Cancer Research (2005)

14   The development of hepatocellular carcinoma is generally preceded by hepatic cirrhosis, which occurs at the end stage of fibrosis, which is a common and potentially lethal problem in chronic liver disease in Asia. The development of microarrays that permits us to monitor transcriptomes on a genome-wide scale has dramatically expedited a comprehensive understanding of the disease process. Here, we used dimethylnitrosamine (DMN), a potent hepatotoxin for necroinflammatory, to induce rat hepatic fibrosis. During the 6-week time course period, histopathological, biochemical and quantitative RT-PCR analyses, confirmed incidence of necroinflammatory and hepatic fibrosis in the established rat model system. By using Affymetrix microarry chip (RG-U34A), hierarchical clustering of samples correctly identified by both 1.5-fold change and flag selection, and then 273 differentially expressed genes were clustered in hepatic fibrosis tissues. Hierarchical clustering of gene expression levels identified several stage-characteristic, functionally related clusters, encoding proteins that were related to metabolism, cell growth and/or maintenance and response to external by gene ontology database (GO). Among these genes, there are 44 necroinflammatory-related and 62 fibrosis-related potential markers or drug targets. The molecular portraits of hepatic fibrosis in this study may provide novel biological insights for the development of earlier liver damage molecular classifiers.
Clinical and Chemical Studies in Human Lactation--VI
Authors: F. E. Hytten
Journal: BMJ (1954)

CHILDHOODMEDICBALJOAL on outdated material it is not likely that any borough has moved from one extreme to the other in social grading.The trend of the incidence of measles in both these groups of boroughs was very similar, and there was no difference of any importance between them.A summary of their positions is given in Table III.It appears from these values that the relative incidence of measles was constant during the period, although Group 1 had relatively a larger outbreak than Group 2 in 1950 owing to a summer rise in incidence.The introduction of the National Health Service in 1948 did not have any differential effect on the incidence.In recent years the measles attack rate has been twice as large among pre-school children as among schoolchildren, and the ratio of these attack rates has been practically constant during the past nine years. SummaryThe number of notifications of scarlet fever, whooping-cough, and measles rose in the six months preceding the operation of the National Health Ser- vice in 1948 and has remained above the level prevailing in 1946-7.Scarlet Fever.-Although the incidence in the first quarter of 1948 was unusually high the subsequent level of the notifications does not suggest that the prevalence of scarlet fever has undergone much change in recent years.There is, however, a suggestion that since 1948 the disease has tended to be more concentrated on the pre-school child.Whooping-cough.-A large increase in the numbers of notifications has occurred since 1948.If the prewar estimate that 70% of the child population have an attack of whooping-cough before age 15 is still valid, then only about one-half of the cases are being notified.But if immunization against whooping-cough has been carried out on large enough numbers it is possible that the higher level of notifications since 1948 is due to a real increase in prevalence.Measles.-The level of notifications of measles has increased in recent years.The whole of the rise in 1948 cannot be explained by increased case-finding and reporting, and it seems that there was a real rise in prevalence just before the operation of the National Health Service.The proportion of children under 15 who suffer a notifi- able attack of measles has risen from about one-half in the early 1940's to about two-thirds in the last five years.It seems probable that there has been a real increase in prevalence during these years.
Relationship between survival to breast cancer and level of HER2 expression by immunohistochemistry.
Authors: Louise Provencher, Caroline Diorio, Christine Desbiens, Brigitte Poirier, Eric Poirier, Dominique Boudreau, Catherine Doyle, Ion Popa, Isabelle Gagné, Jean-Charles Hogue, Julie Lemieux
Journal: Journal of Clinical Oncology (2017)

e13078 Background: Central review of NSABP B-31 showed that some central-review HER2-negative patients benefited from trastuzumab, but survival according to different levels of HER2 expression by immunohistochemistry (IHC) is unknown. The aim of the present study was to examine the survival of trastuzumab-naïve patients with breast cancer according to the level of HER2 expression by IHC. Methods: This was a retrospective study of all women who were treated for an invasive breast cancer at the Centre des maladies du Sein Deschênes-Fabia (Quebec City, Province of Quebec, Canada) between July 1999 and December 2010. Patients were grouped according to the HER2 status by IHC of their primary cancer (0 vs. 1+ vs. 2+ vs. 3+). Survival was obtained from the death registry of the Ministry of Health. Follow-up was censored on December 31 st , 2012. Results: During the study period, 2571 patients with invasive breast cancer, with available HER2 status by IHC and survival data, and naïve to anti-HER2 therapy were treated at our center. Both 5- and 9-year overall survival (OS) decreased with increasing HER2 expression by IHC (9-year OS: 0: 86.2% vs. 1+: 71.3% vs. 2+: 73.9% vs. 3+: 69.3%; unadjusted log-rank test: P &lt; 0.0001; adjusted P = 0.04 for 3+). Both 5- and 9-year breast cancer-specific survival (BCSS) decreased with increasing HER2 expression by IHC (9-year BCSS: 0: 90.7% vs. 1+: 81.8% vs. 2+: 77.0% vs. 3+: 75.4%; unadjusted log-rank test: P &lt; 0.0001; adjusted P = 0.04 for 3+). Conclusions: Survival among trastuzumab-naïve breast cancer patients seems to follow a continuum across HER2 expression by IHC.
Case 2-1995
Authors: W.S. McDougal, V. Nickeleit
Journal: New England Journal of Medicine (1995)

Presentation of CaseA 71-year-old man was admitted to the hospital because of masses in the pancreas, presacral region, and left kidney, with left hydronephrosis.The patient had a 2-year history of “tuberculous pleurisy” 47 years earlier in Europe, where he was born; pleural fluid was drained, and he received no antituberculous chemotherapy in later years. Twenty-eight years before admission he was first seen at this hospital because of chronic prostatitis with recurrent episodes of cystitis. Sixteen years before admission he had bilateral flank pain; an intravenous urographic examination showed no abnormality except for a moderate volume of residual urine. . . .
Efficacy, safety, and effect on sexual behaviour of on-demand pre-exposure prophylaxis for HIV in men who have sex with men: an observational cohort study
Authors: Jean-Michel Molina, Isabelle Charreau, Bruno Spire, Laurent Cotte, Julie Chas, Catherine Capitant, Cecile Tremblay, Daniela Rojas-Castro, Eric Cua, Armelle Pasquet, Camille Bernaud, Claire Pintado, Constance Delaugerre, Luis Sagaon-Teyssier, Soizic Le Mestre, Christian Chidiac, Gilles Pialoux, Diane Ponscarme, Julien Fonsart, David Thompson, Mark A Wainberg, Veronique Doré, Laurence Meyer, L Meyer, C Capitant, I Charreau, E Netzer, N Leturque, J Binesse, V Foubert, M Saouzanet, F Euphrasie, D Carette, B Guillon, Y Saïdi, J P Aboulker, B Spire, M Suzan, G Cattin, B Demoulin, L Sagaon-Teyssier, N Lorente, V Doré, E Choucair, S Le Mestre, A Mennecier, N Etien, M C Simon, A Diallo, S Gibowski, J F Delfraissy, D Thompson, J Sas, J Pankovitch, M Klein, A Anis, Jean-Michel Molina, Mark A Wainberg, Benoit Trottier, Cécile Tremblay, Jean-Guy Baril, Gilles Pialoux, Laurent Cotte, Antoine Chéret, Armelle Pasquet, Eric Cua, Michel Besnier, Willy Rozenbaum, Christian Chidiac, Constance Delaugerre, Nathalie Bajos, Julie Timsit, Gilles Peytavin, Julien Fonsart, Isabelle Durand-Zaleski, Laurence Meyer, Jean-Pierre Aboulker, Bruno Spire, Marie Suzan-Monti, Gabriel Girard, Daniela Rojas Castro, Marie Préau, Michel Morin, David Thompson, Catherine Capitant, Anaïs Mennecier, Elias Choucair, Véronique Doré, Marie-Christine Simon, Isabelle Charreau, Joanne Otis, France Lert, Alpha Diallo, Séverine Gibowski, Cecile Rabian
Journal: The Lancet HIV (2017)
Malignant T cells activate endothelial cells via IL-17 F
Authors: B Lauenborg, I V Litvinov, Y Zhou, A Willerslev-Olsen, C M Bonefeld, C Nastasi, S Fredholm, L M Lindahl, D Sasseville, C Geisler, M M Wasik, T Krejsgaard, L M R Gjerdrum, L Iversen, N Odum, A Woetmann
Journal: Blood Cancer Journal (2017)
Fluticasone Furoate, Vilanterol, and Lung Function Decline in Patients with Moderate Chronic Obstructive Pulmonary Disease and Heightened Cardiovascular Risk
Authors: Peter M. A. Calverley, Julie A. Anderson, Robert D. Brook, Courtney Crim, Natacha Gallot, Sally Kilbride, Fernando J. Martinez, Julie Yates, David E. Newby, Jørgen Vestbo, Robert Wise, Bartolomé R. Celli
Journal: American Journal of Respiratory and Critical Care Medicine (2017)

Many patients with chronic obstructive pulmonary disease (COPD) have an accelerated loss of lung function. It is unclear whether drug treatment can modify this in patients with moderately severe disease.In a prespecified analysis of the key secondary outcome in SUMMIT (Study to Understand Mortality and Morbidity), we investigated whether the inhaled corticosteroid fluticasone furoate (FF; 100 μg), the long-acting β-agonist vilanterol (VI; 25 μg), or their combination (FF/VI) modified the rate of decline in FEV1 compared with placebo. We also investigated how baseline covariates affected this decline.Spirometry was measured every 12 weeks in this event-driven, randomized, placebo-controlled trial of 16,485 patients with moderate COPD and heightened cardiovascular risk. An average of seven spirometric assessments per subject among the 15,457 patients with at least one on-treatment measurement were used in the analysis of rate of FEV1 decline. All statistical comparisons are considered nominal.The adjusted rates of FEV1 decline were -46 ml/yr (-3.0% of baseline) with placebo, -47 ml/yr (-3.1%) with VI, -38 ml/yr (-2.5%) with FF, and -38 ml/yr (-2.3%) with FF/VI. FF-containing regimens had lower rates of decline than placebo (P < 0.03), and FF/VI had a lower rate of decline than VI alone (P < 0.005). The FEV1 decline was faster in current smokers, those with a lower body mass index, males, and patients with established cardiovascular disease.In patients with moderate COPD and heightened cardiovascular risk, FF alone or in combination with VI appears to reduce the rate of FEV1 decline. Clinical trial registered with www.clinicaltrials.gov (NCT01313676).
Heterogeneity of neuroblastoma cell identity defined by transcriptional circuitries
Authors: Valentina Boeva, Caroline Louis-Brennetot, Agathe Peltier, Simon Durand, Cécile Pierre-Eugène, Virginie Raynal, Heather C Etchevers, Sophie Thomas, Alban Lermine, Estelle Daudigeos-Dubus, Birgit Geoerger, Martin F Orth, Thomas G P Grünewald, Elise Diaz, Bertrand Ducos, Didier Surdez, Angel M Carcaboso, Irina Medvedeva, Thomas Deller, Valérie Combaret, Eve Lapouble, Gaelle Pierron, Sandrine Grossetête-Lalami, Sylvain Baulande, Gudrun Schleiermacher, Emmanuel Barillot, Hermann Rohrer, Olivier Delattre, Isabelle Janoueix-Lerosey
Journal: Nature Genetics (2017)
Re-treatment with radium-223: first experience from an international, open-label, phase I/II study in patients with castration-resistant prostate cancer and bone metastases
Authors: O. Sartor, D. Heinrich, N. Mariados, M.J. Méndez Vidal, D. Keizman, C. Thellenberg Karlsson, A. Peer, G. Procopio, S.J. Frank, K. Pulkkanen, E. Rosenbaum, S. Severi, J.M. Trigo Perez, V. Wagner, R. Li, L.T. Nordquist
Journal: Annals of Oncology (2017)

Six radium-223 injections at 4-week intervals is indicated for patients with castration-resistant prostate cancer and symptomatic bone metastases. However, patients usually develop disease progression after initial treatment. This prospective phase I/II study assessed re-treatment safety and efficacy of up to six additional radium-223 injections.Patients had castration-resistant prostate cancer and bone metastases and six initial radium-223 injections with no on-treatment bone progression; all had subsequent radiologic or clinical progression. Concomitant agents were allowed at investigator discretion, excluding chemotherapy and initiation of new abiraterone or enzalutamide. The primary endpoint was safety; additional exploratory endpoints included time to radiographic bone progression, time to total alkaline phosphatase and prostate-specific antigen progression, radiographic progression-free survival, overall survival, time to first symptomatic skeletal event (SSE), SSE-free survival, and time to pain progression.Among 44 patients, 29 (66%) received all six re-treatment injections. Median time from end of initial radium-223 treatment was 6 months. Forty-one (93%) reported ≥1 treatment-emergent adverse event. No grade 4-5 hematologic treatment-emergent adverse events occurred. Only one (2%) patient had radiographic bone progression; eight (18%) had radiographic soft tissue tumor progression (three lymph node and five visceral metastases). Median times to total alkaline phosphatase and prostate-specific antigen progression were not reached and 2.2 months, respectively. Median radiographic progression-free survival was 9.9 months (12.8-month maximum follow-up). Five (11%) patients died and eight (18%) experienced first SSEs. Median overall survival, time to first SSE, and SSE-free survival were not reached. Five (14%) of 36 evaluable patients (baseline worst pain score ≤7) had pain progression. After 2 years of follow-up, 28 (64%) patients died, and the median overall survival was 24.4 months.Re-treatment with a second course of six radium-223 injections after disease progression is well tolerated, with minimal hematologic toxicity and low radiographic bone progression rates in this small study with limited follow-up. Favorable safety and early effects on disease progression indicate that radium-223 re-treatment is feasible and warrants further evaluation in larger prospective trials.
Multilayered Nanofilms: Multilayer Nanofilms via Inkjet Printing for Stabilizing Growth Factor and Designing Desired Cell Developments (Adv. Healthcare Mater. 14/2017)
Authors: Moonhyun Choi, Hee Ho Park, Daheui Choi, Uiyoung Han, Tai Hyun Park, Hwankyu Lee, Juhyun Park, Jinkee Hong
Journal: Advanced Healthcare Materials (2017)

Multilayered nanofilm fabricating system with inkjet printing is developed by Jinkee Hong and co-workers in article number 1700216. Inkjet printed nanofilms are composed of polymeric materials and bioactive materials, especially with enhanced structural stability of growth factor (basic Fibroblast Growth Factor). Growth factors containing nanofilms are effective in maintaining undifferentiated pluripotent stem cells by promoting proliferation and expansion.
A Case of Heart Failure after Treatment with Anti–PD-1 Antibody Followed by Adoptive Transfer of Cytokine-Activated Killer Cells in a Recurrent Lung Cancer Patient
Authors: Hideki Kimura, Yuichi Tounai, Kaoru Nagato, Jun-ichi Morimoto, Yuichi Tounai
Journal: Journal of Thoracic Oncology (2017)
Autophagy and Inflammation
Authors: Yu Matsuzawa-Ishimoto, Seungmin Hwang, Ken Cadwell
Journal: Annual Review of Immunology (2017)

The cellular degradative pathway of autophagy has a fundamental role in immunity. Here, we review the function of autophagy and autophagy proteins in inflammation. We discuss how the autophagy machinery controls the burden of infectious agents while simultaneously limiting inflammatory pathologies, which often involves processes that are distinct from conventional autophagy. Among the newly emerging processes we describe are LC3-associated phagocytosis and targeting by autophagy proteins, both of which require many of the same proteins that mediate conventional autophagy. We also discuss how autophagy contributes to differentiation of myeloid and lymphoid cell types, coordinates multicellular immunity, and facilitates memory responses. Together, these functions establish an intimate link between autophagy, mucosal immunity, and chronic inflammatory diseases. Finally, we offer our perspective on current challenges and barriers to translation.
CONSORT Extension for Chinese Herbal Medicine Formulas 2017: Recommendations, Explanation, and Elaboration
Authors: Chung-wah Cheng, Tai-xiang Wu, Hong-cai Shang, You-ping Li, Douglas G. Altman, David Moher, Zhao-xiang Bian
Journal: Annals of Internal Medicine (2017)

Chinese herbal medicine (CHM) formulas are the major components of traditional Chinese medicine (TCM) interventions. The general reporting quality of randomized controlled trials (RCTs) of CHM formulas is disappointing, although CONSORT (Consolidated Standards of Reporting Trials) Statement extensions for herbal medicinal interventions and acupuncture interventions are available. A group of TCM clinical experts, methodologists, epidemiologists, and editors has developed this CONSORT Extension for CHM Formulas (CONSORT-CHM Formulas 2017) through a comprehensive process, including publication of the draft version, solicitation of comments, revision, and finalization. The CONSORT 2010 Statement was extended by introducing the idea of TCM Pattern and the features of CHM formulas. One new checklist subitem, keywords, was added to facilitate indexing and data searching. Seven of the 25 CONSORT checklist items, namely title and abstract, background and objectives, participants, interventions, outcomes, generalizability, and interpretation, are now elaborated, and the explanation of harms specific to CHM formulas is revised. Illustrative examples and explanations are also provided. The group hopes that CONSORT-CHM Formulas 2017 can improve the reporting quality of RCTs of CHM formulas.
Hepatitis E virus infection and acute non-traumatic neurological injury: A prospective multicentre study
Authors: Harry R. Dalton, Jeroen J.J. van Eijk, Pascal Cintas, Richie G. Madden, Catherine Jones, Glynn W. Webb, Benjamin Norton, Julie Pique, Suzanne Lutgens, Nikki Devooght-Johnson, Kathy Woolson, John Baker, Maria Saunders, Liz Househam, James Griffiths, Florence Abravanel, Jacques Izopet, Nassim Kamar, Nens van Alfen, Baziel G.M. van Engelen, Jeremy G. Hunter, Annemiek A. van der Eijk, Richard P. Bendall, Brendan N. Mclean, Bart C. Jacobs
Journal: Journal of Hepatology (2017)
Ultracentrifugal Studies of Some Complexes Obtained From Mouse Milk, Mammary Tumor, and Other Tissues
Authors: Herbert Kahler, W. Ray Bryan, H. M. Sipe
Journal: JNCI Journal of the National Cancer Institute (1943)

Journal Article Ultracentrifugal Studies of Some Complexes Obtained From Mouse Milk, Mammary Tumor, and Other Tissues Get access Herbert Kahler, Herbert Kahler senior biophysicist Search for other works by this author on: Oxford Academic PubMed Google Scholar W. Ray Bryan, W. Ray Bryan biologist Search for other works by this author on: Oxford Academic PubMed Google Scholar H. M. Sipe H. M. Sipe technical assistance of scientific aide National Cancer Institute, National Institute of Health, United States Public Health Service Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 4, Issue 1, August 1943, Pages 37–45, https://doi.org/10.1093/jnci/4.1.37 Published: 01 August 1943
Evaluating treatment patterns of relapsed acute myeloid leukemia (AML) among the elderly in the United States.
Authors: Qisu Zhang, Lin Xie, Onur Baser, Michael McGuire
Journal: Journal of Clinical Oncology (2017)

e18161 Background: The type and place of treatment in relapsed AML has not been explored in a large national data set. The goal of this study is to examine treatment patterns among elderly patients (pts) with relapsed AML. Methods: Elderly pts (age ≥ 65 years) with an AML diagnosis (ICD-9-CM: 205.x) were identified using Medicare data from Jan 2010 to Dec 2014. The index date was the first AML treatment date within 30 days of diagnosis. Relapsed pts were identified with ICD-9-CM 205.02 or a claim for AML therapy after a ≥ 120-day treatment-free gap. Pts were required to have continuous enrollment 12 months before AML diagnosis and 6 months after, and no pre-diagnosis claims for blood cancer, chemotherapy, radiotherapy, or AML-related surgery. Transfusion dependence (TD) was defined as ≥ 2 transfusions within an 8-week period. The type and place of treatment for relapsed pts with both 1st- and 2nd-line therapy was examined. Results: 1,726 pts who received treatment for relapsed AML were included in the study. The 30- and 60-day mortality rates from the date of relapse treatment were 19.6% and 33.6%. During 1st-line therapy, 28.6% of pts received inpatient chemotherapy only, 59.1% received both inpatient and outpatient therapy (median inpatient length of stay [LOS]: 32 days), and 3.8% received outpatient therapy only. The most frequent outpatient therapies were hypomethylating agents and supportive therapies, e.g. G-CSF, anti-infectives. 11.3% of inpatients were given a bone marrow transplant (BMT). Additionally, 90.1% of pts received blood transfusions at an average rate of 8.9 per year, and 77.2% of pts were TD. During 2nd-line therapy, 19.6% of relapsed pts received inpatient chemotherapy only, 41.2% received both inpatient and outpatient therapy (median inpatient LOS: 7 days), and 9.3% received outpatient therapy only. Outpatient therapies were similar to those seen at 1st line. 10.3% of inpatients were given a BMT. 80.9% of pts received blood transfusions at an average rate of 19.7 per year, and 60.4% of pts were TD. Conclusions: Current treatment options available for relapsed AML pts are associated with a significant treatment burden at both 1st and 2nd lines of therapy, as well as a high early-mortality rate.
Mutational Landscape, Clonal Evolution Patterns and Role of RAS Mutations in Relapsed Acute Lymphoblastic Leukemia
Authors: Koichi Oshima, Hossein Khiabanian, Ana Carolina da Silva Almeida, Gannie Tzoneva, Francesco Abate, Alberto Ambesi-Impiombato, Marta Sanchez-Martin, Zachary Carpenter, Alexander Penson, Arianne Perez-Garcia, Cornelia Eckert, Concepción Nicolás, Milagros Balbin, Maria Luisa Sulis, Motohiro Kato, Katsuyoshi Koh, Maddalena Paganin, Giuseppe Basso, Julie M. Gastier-Foster, Meenakshi Devidas, Mignon L. Loh, Renate Kirschner-Schwabe, Teresa Palomero, Raul Rabadan, Adolfo A. Ferrando
Journal: Blood (2016)
Erythematous, Burning and Painful Scrotal Nodules
Authors: Lacey Vence, Janine C. Malone
Journal: JAMA Dermatology (2017)

A man in his 60s who had been treating intertrigo of the groin with a combination of clotrimazole and hydrocortisone developed bright red, burning and painful nodules around his scrotum. What is your diagnosis?
Abstract 15420: Short-Term Rapid Atrial Pacing Augmented Gene Expression of Proinflammatory Molecules in the Rat Liver
Authors: Naomi Kanamori, Takeshi Kato, Takanori Yaegashi, Soichiro Usui, Hiroshi Furusho, Shin-ichiro Takashima, Hisayoshi Murai, Shuichi Kaneko, Masayuki Takamura
Journal: Circulation (2016)

Background: Recent evidences imply close relationship between atrial fibrillation (AF) and inflammation. However, it is still controversial whether inflammation is a cause or a consequence of AF. T...